Netherton Syndrome
Symptoms, Doctors, Treatments, Advances & More

Learn About Netherton Syndrome

What is the definition of Netherton Syndrome?

Netherton syndrome is a disorder that affects the skin, hair, and immune system. Newborns with Netherton syndrome have skin that is red and scaly (ichthyosiform erythroderma), and the skin may leak fluid. Some affected infants are born with a tight, clear sheath covering their skin called a collodion membrane. This membrane is usually shed during the first few weeks of life. Because newborns with this disorder are missing the protection provided by normal skin, they are at risk of becoming dehydrated and developing infections in the skin or throughout the body (sepsis), which can be life-threatening. Affected babies may also fail to grow and gain weight at the expected rate (failure to thrive). The health of older children and adults with Netherton syndrome usually improves, although they often remain underweight and of short stature.

What are the causes of Netherton Syndrome?

Netherton syndrome is caused by mutations in the SPINK5 gene. This gene provides instructions for making a protein called LEKT1. LEKT1 is a type of serine peptidase inhibitor. Serine peptidase inhibitors control the activity of enzymes called serine peptidases, which break down other proteins. LEKT1 is found in the skin and in the thymus, which is a gland located behind the breastbone that plays an important role in the immune system by producing white blood cells called lymphocytes. LEKT1 controls the activity of certain serine peptidases in the outer layer of skin (the epidermis), especially the tough outer surface known as the stratum corneum, which provides a sturdy barrier between the body and its environment. Serine peptidase enzymes are involved in normal skin shedding by helping to break the connections between cells of the stratum corneum. LEKT1 is also involved in normal hair growth, the development of lymphocytes in the thymus, and the control of peptidases that trigger immune system function.

How prevalent is Netherton Syndrome?

Netherton syndrome is estimated to affect 1 in 200,000 newborns.

Is Netherton Syndrome an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Netherton Syndrome Local Doctors?
Elite in Netherton Syndrome
Elite in Netherton Syndrome
Referral may be required
Paris, FR 

Alain Hovnanian practices practicing medicine in Paris, France. Mr. Hovnanian is rated as an Elite expert by MediFind in the treatment of Netherton Syndrome. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Netherton Syndrome, Olmsted Syndrome, Dystrophic Epidermolysis Bullosa, and Epidermolysis Bullosa.

Elite in Netherton Syndrome
Elite in Netherton Syndrome
Referral may be required
30 Guilford Street, 
London, ENG, GB 

Wei-li Di practices practicing medicine in London, United Kingdom. Di is rated as an Elite expert by MediFind in the treatment of Netherton Syndrome. They are also highly rated in 4 other conditions, according to our data. Their clinical expertise encompasses Netherton Syndrome, Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa, and Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Netherton Syndrome
Elite in Netherton Syndrome
Referral may be required

Great Ormond Street Hospital

London, ENG, GB 

Waseem Qasim practices practicing medicine in London, United Kingdom. Mr. Qasim is rated as an Elite expert by MediFind in the treatment of Netherton Syndrome. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Netherton Syndrome, Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa, Primary Immunodeficiency (PID), and Bone Marrow Transplant.

What are the latest Netherton Syndrome Clinical Trials?
A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome

Summary: This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multicenter, Open-label Study of QRX003 Lotion in Participants With Netherton Syndrome

Summary: This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.

Who are the sources who wrote this article ?

Published Date: March 01, 2014
Published By: National Institutes of Health